当前位置:首页>产品中心>单抗/多抗>Anti-Human CAMK2D Polyclonal Antibody|抗人CAMK2D多克隆抗体(靶标:人钙/钙调蛋白依赖性蛋白激酶IIδ)

Anti-Human CAMK2D Polyclonal Antibody|抗人CAMK2D多克隆抗体(靶标:人钙/钙调蛋白依赖性蛋白激酶IIδ)

  • 货号:RB9THC230014
  • 价格:面议
  • 点击:330

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Mouse, Human, Rat
靶标CAMK2D, CAMKD, CaM kinase II subunit delta, CaMK-II subunit delta, Calcium/calmodulin-dependent protein kinase type II subunit delta, EC:2.7.11.17
免疫原E. coli - derived recombinant Human CAMK2D (Thr8-Asn313).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q13557
背景信息

Calcium/calmodulin-dependent protein kinase type II subunit delta (CAMK2D) is a ~56 kDa protein. Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules to regulate heart function. In its activated form, is involved in the pathogenesis of dilated cardiomyopathy and heart failure. Contributes to cardiac decompensation and heart failure by regulating SR Ca(2+) release via direct phosphorylation of RYR2 Ca(2+) channel on 'Ser-2808'. In the nucleus, phosphorylates the MEF2 repressor HDAC4, promoting its nuclear export and binding to 14-3-3 protein, and expression of MEF2 and genes involved in the hypertrophic program.

1. Little, GH. et al. (2007) The Journal of biological chemistry 282, 7219-31. PMID: 17179159
2. Rose, AJ. et al. (2006) The Journal of physiology 574, 889-903. PMID: 16690701
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 575
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 380
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 595
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 333
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 470
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 620
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 556
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 664
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 508
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 319
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 461
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 364
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 594
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 533
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 496
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody|抗埃罗妥珠单抗非中和重组抗体(靶标:埃罗妥珠单抗非中和抗体) 636
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 315
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 370
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 353
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 367
总计 33037 个记录,共 1652 页,当前第 1649 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00